Faculty Karl M. Nobert, Esq.

Food and Drug Regulatory Attorney

Washington, DC

Course Description:

Have a Headache? Back from lunch and now experiencing mild occasional Heart Burn? Suffer from Allergies? Been stuck in bed with a Cough, Sore Throat, Nasal Congestion and a Fever you just can’t shake? Pitched the tent in Poison Ivy on last weekend’s family camping trip by mistake? Use Deodorant?  

Over-the-Counter Drug Products or “OTC Drugs” include many of the well-known products that we use to treat or control the symptoms of occasional and moderate health conditions. Available without a prescription and for purchase directly off-the-shelf, OTC drug products currently represent nearly 60% of all drug products sold in the United States.

Anyone who has ever suffered from these or similar occasional symptoms and conditions has likely relied upon an Over-the-Counter Drug Product or “OTC Drug” to feel better. Go into any CVS Retail Pharmacy, Wal-Mart, Meijer Grocery Story, Rite Aid Retail Pharmacy or Target in the United States; you are guaranteed to find store shelves lined with hundreds or even thousands of different OTC Drug products.  Some of the most recognized OTC drug products include ibuprofen tablets, anti-itch creams, nasal decongestant sprays, cough syrups, antacids, allergy medicines and topical pain relievers. Available without a prescription and bought right off the store shelf, OTC drugs are safe and effective when properly labeled and used as intended.

The U.S. Food and Drug Administration’s (“FDA”) is responsible for the regulation and oversight of the U.S. OTC drug market. Congress has granted FDA regulatory authority over the formulation, manufacturing, labeling, marketing and promotion; and import / export of OCT drug products into the U.S.  Under this current regulatory regime, there are 3 pathways that a company may follow to enter the OTC drug market including (a) following an appropriate Drug Monograph; (b) with an Agency approved New Drug Application (“NDA”); or (c) via the currently popular Rx-to-OTC Switch Process. 

 Market studies suggest that there are currently over 300,000 OTC Drugs being marketed and sold in the U.S. today and that number is growing daily. This amounts to almost 60% of the total U.S. drug market (by purchases) and this number is expected to grow in the future. Based on these predictions alone, this is a profitable market and growth potential that drug and health product companies cannot afford to ignore.

If you can cook and follow a recipe; then you can make an OTC Drug Product with access to the necessary resources and an appropriate facility. This course is intended to provide attendees with the knowledge and skills needed to develop and produce an OTC Drug Product for marketing and sale in the U.S. Attendees will gain an understanding of the various available options for producing and selling an OTC Drug Product, will leave the workshop with an understanding of the U.S. Food and Drug Administration’s (“FDA”) regulation of such products, and will be provided with strategic recommendations for mitigating the risk of enforcement action in the future.  

Course Outline: Agenda

Day One (10:00am- 4:00pm EST ) 

Overview of Drug Regulation in the United States

  • Role and Function of FDA Generally
  • FDA’s purpose and mission
  • FDA’s jurisdiction
  • FDA’s six “product centers”
  • Center for Food Safety and Applied Nutrition (CFSAN)
  • Center for Drug Evaluation and Research (CDER)
  • Center for Biologics Evaluation and Research (CBER)
  • Center for Devices and Radiological Health (CDRH)
  • Center for Tobacco Products
  • Center for Veterinary Medicine (CVM)
  • FDA’s operation

Structure of FDA: Specifics of CDER

  • CDER’s Mission
  • CDER’s Jurisdiction
  • CDER’s Organization (discuss divisions and duties within each office)

Intro to the FDCA, Regulations, and Guidance Documents 

  • Overview of FDCA and regulations
  • Introduction to FDA guidance

OTC drugs v. Rx Drugs

  • Differences between the two
  • How to distinguish

History of Regulation of OTC Drugs in the US

  • Statutory and Regulatory Authority for OCT Drugs
  • 1906: Food and Drug Act
  • 1938: Federal Food Drug Cosmetic Act (FFDCA) drug safety requirement.
  • 1951: Durham-Humphrey Amendments to Federal Food, Drug and Cosmetic Act (FFDCA) designated drugs that cannot be used safely without professional supervision as prescription drugs and all other drugs as OTC.
  • 1962: Drug Amendments
  • In order for an OTC drug active ingredient to be included in an OTC monograph it must have been marked prior to May 11, 1972.
  • Two legal pathways for OTC drug marketing post 1938.
  • Marketing in compliance with drug monograph
  • Marketing under the authority of an approved New Drug Application (NDA).
  • Other Relevant Laws:
  • The Federal Trade Commission Act
  • The Fair Packaging and Labeling Act
  • The Lanham Act
  • State Laws

OTC Drug Review Process

  • “Drug” Definition
  • See 21 U.S.C. § 321(g)(1)
  • Criteria
  • Commercialization Pathways
  • New Drug Approval Process
  • The NDA
  • An Rx-to-OTC Switch
  • The OTC Drug Monograph Process 
  • New Drug Approval Process 
  • NDA
  • Rare for a company to pursue an approved NDA for a non-prescription drug because of the expense and effort involved with obtaining FDA approval.  
  • Regulatory Procedure
  • Rx-to-OTC
  • The Rx-to-OTC Switch regulatory pathway is becoming increasingly popular as companies look for ways to extend the life cycle of their branded prescription products but similar to the option above, an Rx-to-OTC Switch requires FDA’s approval of an NDA. 
  • OTC Drug Monograph System
  • Developed in the 1970’s in response to a whole class of marketed non-prescription drug products that existed in the market that had never been reviewed for safety and effectiveness.  
  • Attempt to “clean up” the market
  • Development of the monograph process (or “OTC Drug Review”)
  • OTC drugs as Generally Recognized as Safe & Effective (“GRAS&E”).

OTC Drug Monographs

  • Definition & Purpose
  • Policy Reasons Behind the Monograph Process
  • Process
  • Notice of Proposed Monograph
  • Proposed Final Monograph
  • Final Monograph

Final OTC monograph establishes the acceptable:

  • active ingredients
  • concentration of the active ingredients
  • therapeutic claims
  • indications
  • labeling/warning requirements
  • directions for use

Marketing the OTC drug product when the Monograph is not final


Day Two (10:00am - 4:00pm EST ) 

2020 Changes to the OTC Monograph System Under the CARES Act

  • The FDA’s OTC Monograph Reform, Over-the-Counter Monograph User Fee Program (“OMUFA”), and Over-the-Counter Monograph Order Request (“OMOR”)
  • What are Order Requests?
  • Impact of Changes on Current OTC Monograph System
  • What to do about product labels and labeling?
  • Examples of Modifications as Applied to Existing OTC Product Categories

OMUFA and the Coronavirus Aid, Relief, and Economic Security (CARES) Act

  • Complying with the FDA’s new OTC regulatory framework
  • Advantages of a comprehensive, global strategy for regulatory compliance
  • Exclusivity for OT

What to do about the Changes? 

  • Adapting to Required Changes
  • Developing a Modification Plan Modifying Existing Systems
  • Revising Standard Operating Procedures
  • Best Practices for Mitigating Potential FTC, State and Third-Party Enforcement Risks
  • Strategic Recommendations

Status of specific OTC Monographs, their included Regulatory Requirements and Strategies for Commercialization

  • Antimicrobial
  • Cold & Cough
  • External Analgesic
  • Internal Analgesic
  • Laxatives
  • Nasal Decongestant
  • Skinning Bleaching
  • Skin Protectants
  • Sunscreens
  • Other Monographs as appropriate.

OTC Drug Ingredients

  • Classification
  • Substantiating the safety and efficacy of a proposed new ingredient
  • Showing why an Ingredient should be included in the Monograph
  • The concept of GRAS

Marketing a drug product that deviates from a final monograph

  • Suitability Petitions

OTC Drug Labels, Labeling, Marketing and Advertising Issues

  • An OTC product's indications are limited to (a) those approved by FDA in the case of an OTC application or an Rx to OTC Switch product, or (b) the uses and indications included in the relevant monograph. 
  • Beyond those indications, other labeled uses and indications are not permitted.

Definitions of the terms “label” and “labeling”

Labeling includes the Immediate Container, Outer Packaging, Package Insert, Client Information Sheet, Shipping Label

Elements of an OTC Drug compliant label

  • Active Ingredient
  • Use
  • Warnings
  • Inactive Ingredients
  • Purpose
  • Directions
  • Other Information

Promotional Materials

  • Brochures, Press Releases, Flyers, Audio and Advertising
  • Written Media, Broadcast Media, Internet Media, Social Media

Strategies for Regulatory Compliance

FDA Enforcement Actions

  • Noncompliance and Enforcement
  • FDA Enforcement Authority over Development, Manufacture, Marketing, and Distribution
  • FDA’s Office of Regulatory Affairs (ORA): Responsible for field activities, imports, inspections, and enforcement policy
  • Local, State, and Tribal governments
  • Types of Enforcement Actions
  • Warning Letters and Untitled Letters
  • Seizures
  • Injunctions
  • Monetary Penalties (21 USC §§ 303 and 307)
  • Criminal Prosecution
  • Debarment

Park Doctrine – Corporate Official Liability under FDCA

Overlapping Agency Jurisdiction – FDA, DOJ, FTC, USDA, and State Agencies

Learning Objectives:

Participants who attend this course will:

  • Gain a comprehensive understanding of how OTC Drug Products are regulated in the U.S. 
  • Learn to distinguish between a potential Rx pharmaceutical product and an OTC drug.
  • Recognize the difference between the various pathways for commercializing an OTC Drug Product.
  • Understand how to identify and successfully navigate an OTC Drug Monograph.
  • Recognize when reliance on a Proposed Rule, Final Rule and/or Drug Monograph is appropriate.
  • Understand how to determine whether an Ingredient is considered Safe or GRAS/E for use in an OTC Drug and understand the difference between Category I, II and II Ingredient designations.
  • Identify the required elements of a compliant OTC Drug Label.
  • Take away strategies for marketing and promoting OTC drug products, and for mitigating potential enforcement risks.
  • Possess a working knowledge of the Rx-to-OTC Switch Process.
  • Review and evaluate several of FDA’s current OTC Monographs.

Who Will Benefit

This includes individuals responsible for overseeing regulatory affairs, developing strategies for obtaining drug product approvals and those tasked with ensuring corporate compliance. Among others, this includes:

  • Senior quality managers
  • Quality professionals
  • Regulatory professionals
  • Compliance professionals
  • Production supervisors
  • Manufacturing engineers
  • Production engineers
  • Design engineers
  • Labelers and Private Labelers
  • Contract Manufacturers
  • Importers and Custom Agents
  • U.S. Agents of Foreign Corporations
  • Process owners
  • Quality engineers
  • Quality auditors
  • Document control specialists
  • Record retention specialists
  • Medical affairs
  • Legal Professionals
  • Financial Advisors and Institutional Investors
  • Consultants, Inspectors and cGMP Experts
Karl M. Nobert

Karl M. Nobert


Karl focuses his practice in FDA Regulatory law, representing U.S. and international clients in the food and drug industries with regard to pharmaceuticals and OTC drugs, biologics, medical devices, food and beverages including dairy products, cosmetics, vitamins and dietary supplements, and veterinary products.

He has particular experience in the areas of prescription drugs and regenerative medicine, and has counseled numerous clients seeking FDA approval for Rx drugs and cellular-based products to treat both humans and animals.

Choose a Purchase Option


$1,699

One Dial-in One Attendee

Registrations till 30 Nov, 2020 - $1699 Registrations after 30 Nov, 2020 - $1899

$2,950

Corporate Live – Group ( Training DVD Free )

Up to 5 Dial In is allowed from home or office . Training DVD by download will be shared within 24 hrs.

$1,895

Recorded Access Corporate Group

You'll have access to group log-in for an archived recording of the entire 2 day virtual seminar including the Q&A period, for 1 location. You can log in any time of day or night. You'll also receive all presentation materials, plus an audio recording and transcript for the entire session. Delivery is approximately 48 hours after the session